Humanwell Healthcare (600079) Q3 2024 earnings summary

Executive summary

• Revenue for Q3 2024 reached RMB 6.28 billion, up 9.66% year-over-year; year-to-date revenue was RMB 19.14 billion, up 5.70% year-over-year.

• Net profit attributable to shareholders for Q3 was RMB 478.60 million, up 7.57% year-over-year; year-to-date net profit was RMB 1.59 billion, down 10.12% year-over-year.

• Cash flow from operating activities for the first nine months increased 53.35% year-over-year to RMB 1.49 billion.

Financial highlights

• Basic EPS for Q3 was RMB 0.29, up 7.41% year-over-year; year-to-date basic EPS was RMB 0.98, down 10.09% year-over-year.

• Total assets at quarter-end were RMB 37.35 billion, up 3.15% from year-end 2023.

• Shareholders’ equity attributable to listed company shareholders was RMB 17.87 billion, up 4.84% from year-end 2023.

• Non-recurring gains for the first nine months totaled RMB 68.57 million, mainly from government subsidies and asset disposals.

Outlook and guidance

• Management highlighted strengthened accounts receivable management as a driver for improved operating cash flow.